Fast track designation is an FDA program designed to speed up the development and review of drugs that treat serious medical conditions and fill an unmet need. It doesn’t mean a drug is approved or even that it will be. Instead, it opens a faster lane of communication between the drug company and the FDA, with the goal of getting important therapies to patients sooner.
How Fast Track Designation Works
The FDA created the fast track program to reduce the time it takes for promising drugs to move through the development pipeline. Normally, a drug company completes all of its research, packages everything into one massive application, and then submits it to the FDA for a lengthy review. Fast track designation changes that process in a few key ways.
First, it gives drug companies more frequent meetings with the FDA throughout development. These aren’t just courtesy check-ins. They’re working sessions where the company and regulators align on trial design, what data to collect, and how to measure whether the drug is actually working. The company also gets more frequent written feedback from the FDA on things like clinical trial structure and the use of biomarkers (measurable indicators that a drug is having an effect in the body).
Second, and perhaps most importantly, fast track designation makes a drug eligible for rolling review. In a standard process, the FDA won’t even begin looking at an application until every single section is complete and submitted as a package. With rolling review, the company can send completed sections as they finish them, and the FDA starts reviewing right away. This alone can shave months off the timeline.
What It Takes to Qualify
A drug must meet two criteria to receive fast track designation. It must treat a serious condition, and nonclinical or clinical data must show it has the potential to address an unmet medical need. “Serious condition” is broad and covers diseases that have a substantial impact on daily life or are life-threatening. “Unmet medical need” typically means there’s no existing treatment, or the drug could offer a meaningful advantage over what’s currently available.
Drug companies can request the designation at any point during development, from the moment they first file an investigational new drug application all the way up until they apply for marketing approval. Most companies request it during the investigational phase, before they’ve submitted their full application. Once a request is filed, the FDA has 60 days to decide whether the drug qualifies.
What Fast Track Does Not Mean
Fast track designation is not an endorsement of a drug’s safety or effectiveness. It’s a process tool, not a stamp of approval. A drug with fast track designation still has to clear every standard hurdle for approval: it must demonstrate that it works, that its benefits outweigh its risks, and that it can be manufactured reliably. Plenty of fast-tracked drugs ultimately fail in clinical trials and never reach the market.
It’s also worth knowing that the designation is not permanent in the sense that it guarantees smooth sailing. If data collected during development no longer supports the idea that the drug addresses an unmet need, the FDA can revisit the designation. The drug doesn’t get a free pass simply because it was once labeled fast track.
Fast Track vs. Other Expedited Programs
The FDA runs four expedited programs, and they overlap in ways that can be confusing. Fast track is just one of them. Here’s how they compare:
- Fast track provides more frequent FDA communication and rolling review. The bar for entry is a serious condition plus potential to address an unmet medical need. Companies can request it early in development.
- Breakthrough therapy includes everything fast track offers, plus a higher level of organizational commitment from senior FDA managers who provide intensive guidance during clinical trials. The trade-off is a higher bar: preliminary clinical evidence must suggest the drug may offer a substantial improvement over existing therapies. Companies must request it no later than the end of phase II trials.
- Priority review shortens the FDA’s review clock from the standard 10 months to 6 months. It applies at the end of the process, when the company submits its marketing application, and requires that the drug provide a significant improvement in safety or effectiveness over existing treatments.
- Accelerated approval allows the FDA to approve a drug based on a surrogate endpoint (a lab result or physical sign that’s reasonably likely to predict a real clinical benefit) rather than waiting for long-term outcome data. The company then confirms the benefit with post-approval studies.
These programs aren’t mutually exclusive. A single drug can receive fast track designation during development, earn breakthrough therapy status as its data matures, get priority review when its application is submitted, and ultimately be approved through accelerated approval. In 2024, 66% of the 50 new therapies approved by the FDA’s drug evaluation center used at least one of these expedited pathways.
Why It Matters for Patients
For someone with a serious illness and limited treatment options, the practical effect of fast track designation is that promising drugs can reach the market faster. The rolling review process alone eliminates what can amount to months of waiting, since the FDA begins evaluating data as it comes in rather than sitting idle until the full application arrives. More frequent communication between the company and the FDA also reduces the risk of wasted time on poorly designed trials or data the agency won’t accept.
That said, faster doesn’t mean fast. Even with the designation, drug development takes years. Clinical trials still need to enroll patients, collect data, and demonstrate results. Fast track designation removes some bureaucratic friction, but it doesn’t skip the science. The goal is to compress timelines without lowering standards, so that drugs for serious conditions don’t spend longer in the pipeline than they need to.